Welcome to our dedicated page for Voyager Therapeutics news (Ticker: VYGR), a resource for investors and traders seeking the latest updates and insights on Voyager Therapeutics stock.
Voyager Therapeutics, Inc., listed on Nasdaq under the symbol VYGR, is a pioneering gene therapy company dedicated to developing transformative treatments for severe neurological diseases. Founded in 2014 by leaders in the fields of AAV gene therapy and neuroscience, Voyager focuses on conditions like Parkinson's disease, a monogenic form of amyotrophic lateral sclerosis (ALS), and Friedreich's ataxia. Headquartered in Cambridge, Massachusetts, the company leverages its proprietary TRACER™ AAV capsid discovery platform to create gene therapies with high efficacy and broad brain penetration.
The company’s gene therapy platform, TRACER™ (Tropism Redirection of AAV by Cell-type-specific Expression of RNA), allows for the engineering, optimization, and delivery of AAV-based therapies. This platform has enabled the discovery of novel capsids that exhibit enhanced penetration of the blood-brain barrier and targeted delivery to central nervous system (CNS) tissues.
Voyager's pipeline includes several promising programs. The most advanced is the anti-tau antibody VY-TAU01, aimed at treating Alzheimer’s disease and expected to generate key tau PET imaging data by 2026. Other pipeline projects include gene therapies targeting SOD1 for ALS, and FXN gene therapy for Friedreich’s ataxia.
Financially, Voyager maintains a robust balance sheet. As of December 31, 2023, Voyager reported approximately $431 million in pro-forma cash. This financial strength supports the company’s ongoing clinical trials and the advancement of its gene therapy programs. Voyager collaborates with several industry leaders, including Alexion, AstraZeneca Rare Disease, Novartis Pharma AG, Neurocrine Biosciences, Inc., and Sangamo Therapeutics, Inc. These partnerships provide additional resources and expertise to accelerate the development and commercialization of its therapeutic candidates.
Voyager's achievements have garnered attention within the biotechnology industry. The company's commitment to innovation and the development of life-changing treatments makes it a significant player in the field of gene therapy.
For the latest updates, financial results, and news about Voyager Therapeutics, visit their website at www.voyagertherapeutics.com.
Voyager Therapeutics (Nasdaq: VYGR) recently presented new data at the AD/PD Conference in Gothenburg, Sweden, focusing on its anti-tau antibody program for Alzheimer's disease and GBA1 gene therapy for Parkinson's disease. The anti-tau antibody, VY-TAU01, has been selected as the lead candidate with an IND filing expected in H1 2024. In partnership with Neurocrine Biosciences, the GBA1 gene therapy program showed promising results in mouse models, demonstrating significant improvements in efficacy biomarkers. This data reinforces Voyager's commitment to advancing innovative gene therapy approaches in neurology.
Voyager Therapeutics reported transformational progress in 2022, focusing on high-value neurology projects and validating its TRACER™ capsid platform via deals with Pfizer and Novartis. In 2023, it received a $175 million collaboration payment from Neurocrine Biosciences and a $25 million payment from Novartis for capsid licensing. The company selected a tau antibody development candidate for Alzheimer's and expects IND filings for both Alzheimer’s and ALS programs by 2024. Voyager initiated new research initiatives targeting Alzheimer’s disease and Huntington’s disease. Cash reserves stood at $118.8 million, anticipating operational sustainability into 2025.
Voyager Therapeutics (Nasdaq: VYGR) announced that Novartis has exercised options to license capsids from Voyager’s TRACER™ platform for two neurologic disease targets, marking a significant partnership in gene therapy. This exercise includes a $25 million payment and the potential for up to $600 million in milestone payments, alongside tiered royalties on net sales. The agreement may expand to include additional targets over the next 18 months. Voyager retains rights for other applications of its capsids and has already received $54 million upfront from Novartis.
Voyager Therapeutics, Inc. (Nasdaq: VYGR) will release its fourth quarter and full year 2023 financial results on March 7, 2023, before market opens. Following the announcement, a live conference call will take place at 8:30 a.m. ET for a detailed review of the results. Interested participants can register in advance for telephone access and find the live webcast on Voyager's investor relations website. Voyager is focused on gene therapy and neurology, with a pipeline addressing Alzheimer’s disease, ALS, Parkinson’s disease, and Friedreich’s Ataxia through its innovative TRACER™ AAV capsid discovery platform, enhancing target delivery and blood-brain barrier penetration.
Voyager Therapeutics, a biotechnology firm focused on gene therapy and neurology, announced its participation in several upcoming investor conferences. Key events include:
- SVB Securities Global Biopharma Conference (Virtual) – February 16, 2023, at 1:40 p.m. ET
- Cowen 43rd Annual Health Care Conference, Boston, MA – March 6, 2023, at 10:30 a.m. ET
- Oppenheimer 33rd Annual Healthcare Conference (Virtual) – March 13, 2023, at 8:40 a.m. ET
Webcasts of these sessions will be available on Voyager's website for 30 days post-event. The company utilizes its TRACER™ AAV capsid discovery platform to enhance gene therapy delivery and addresses neurological disorders.
Voyager Therapeutics (Nasdaq: VYGR) has announced employment agreements with two new hires that will include non-qualified stock options and restricted stock units. The stock option awards were approved by Voyager's Compensation Committee and became effective on January 23, 2023. One employee received options for 100,000 shares and restricted stock units for 50,000 shares, while the other employee received options for 50,000 shares and restricted units for 25,000 shares. Each stock option has a ten-year term with an exercise price of $9.16 per share. Vesting for these equity awards is tied to continued employment.
Voyager Therapeutics has entered a strategic collaboration with Neurocrine Biosciences to develop gene therapies for neurological diseases, including Parkinson's disease. The deal includes an up-front payment of $175 million, comprising $39 million in equity and potential milestone payments of up to $1.5 billion. Voyager retains options for co-development in the U.S. and will receive royalties on net sales, while Neurocrine acquires rights to multiple therapies. Jude Onyia from Neurocrine will join Voyager's Board of Directors.
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology firm focused on gene therapy, will have its CEO, Alfred W. Sandrock, Jr., present at the 41st Annual J.P. Morgan Healthcare Conference on January 12, 2023, at 10:30 a.m. PT / 1:30 p.m. ET. The presentation will be available via webcast on the company's website and archived for 30 days. Voyager is known for its TRACER™ AAV capsid discovery platform, aiming to enhance gene therapy delivery, with ongoing projects in Alzheimer's, ALS, Parkinson's, and Friedreich's Ataxia.
FAQ
What is the current stock price of Voyager Therapeutics (VYGR)?
What is the market cap of Voyager Therapeutics (VYGR)?
What is Voyager Therapeutics’ primary focus?
What is the TRACER™ platform?
Where is Voyager Therapeutics headquartered?
What are some key programs in Voyager’s pipeline?
Who are some of Voyager’s strategic partners?
What is the financial condition of Voyager Therapeutics?
When was Voyager Therapeutics founded?
What is the significance of VY-TAU01?
How does Voyager’s TRACER platform contribute to their therapies?
Where can I find more information about Voyager Therapeutics?
